DaVita Q1 EPS Jumps 43.5% to $2.87, Raises 2026 Guidance to $14.10–$15.20
DVA•DaVita delivered Q1 adjusted EPS of $2.87, a 43.5% year-over-year gain that beat estimates by 19.1%, and generated $3.42 billion in revenue, up 5.9%. The company raised its 2026 adjusted EPS guidance to $14.10–$15.20, backed by over 10% free cash flow yield and ongoing share buybacks.
1. Q1 Financial Results
DaVita reported adjusted earnings per share of $2.87 for the first quarter, surpassing consensus estimates by 19.1% and representing a 43.5% year-over-year increase.
2. Revenue and Profitability Trends
Revenue grew 5.9% to $3.42 billion as treatment volumes and pricing improvements supported expanding margins, with operating margin rising to 19.1%.
3. Upgraded 2026 Guidance
Management raised full-year 2026 adjusted EPS guidance to a range of $14.10 to $15.20, reflecting confidence in cash flow generation exceeding 10% yield.
4. Price Target Revision
Analysts maintained a Hold rating but increased the price target to $201 from $144, citing stronger-than-expected results and higher forecasted profitability.
